A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

Clinical trial NCT02086175 · COMPLETED

Trial details

NCT number: NCT02086175
Sponsor: Dana-Farber Cancer Institute
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Start date: 2014-12-01
Primary completion: 2019-07-11
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.